Successful treatment of severe generalized pustular psoriasis with basiliximab (interleukin‐2 receptor blocker)
- 1 November 2000
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 143 (5) , 1121-1122
- https://doi.org/10.1046/j.1365-2133.2000.03878.x
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipientsThe Lancet, 1997
- Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: a comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1.Acta Dermato-Venereologica, 1996
- IMMUNOPROPHYLAXIS WITH A MONOCLONAL ANTI-IL-2 RECEPTOR ANTIBODY IN LIVER TRANSPLANT PATIENTS1Transplantation, 1996
- PROLONGED ACTION OF A CHIMERIC INTERLEUKIN-2 RECEPTOR (CD25) MONOCLONAL ANTIBODY USED IN CADAVERIC RENAL TRANSPLANTATIONTransplantation, 1995
- POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN RENAL ALLOGRAFT RECIPIENTSTransplantation, 1993
- The pathophysiology of psoriasisThe Lancet, 1991
- GENERALIZED PUSTULAR PSORIASIS.British Journal of Dermatology, 1968